CDC leadership continues to try manufacture a scientific debate on vaccines where none exists, writes Ben Lopman.

Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout ...

Companies are being too conservative in how they interpret FDA's AI guidance, but the agency can do more to help, too, Tala ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. David Meek bought Bluebird Bio last year ...

Sources confirm to STAT that Marburg cases have been detected in western Uganda, adding another viral hemorrhagic fever ...

The newly cleared device is based around an app that helps a patient manage their diabetes using a treatment plan defined by ...

The Broad Institute of MIT and Harvard is poised to receive a massive injection of cash to fund breakthroughs in the understanding and treatment of bipolar disorder and schizophrenia research. The ...

What is urgently needed is a shift from pathogen-specific diagnostics toward pathogen-agnostic diagnostic systems,” write ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

AI giant Anthropic has already become a dominant player in technology and a household name for everyday users of artificial ...

Anthropic released Claude Science, an application that optimizes its large language model for scientists and, especially, ...

Vijay Kumar is leaving his role as acting director of the office that reviews cell and gene therapies at the FDA, according ...